# A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

> **NCT00853099** · PHASE3 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 274 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** adalimumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00853099
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-05
- **Final completion:** 2013-08
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2014-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853099, "A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00853099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*